Four years after mitapivat’s first U.S. approval, Agios has now lined up a PDUFA date of November 1, 2026, for a sickle cell indication that would represent a mechanistically distinct entry into a disease category that has seen meaningful regulatory activity but still leaves many patients cycling through chronic transfusions and pain crises without adequate control. The FDA’s Priority Review designation compresses the target review window from ten months to six, and the sNDA travels under the accelerated approval pathway, meaning a confirmatory trial must already be underway at the time of any approval decision.
That confirmatory trial, REIGNITE, is the structural obligation Agios cannot defer. The Phase 3 design randomizes approximately 159 participants aged 12 and older in a 2:1 ratio to mitapivat 100 mg twice daily or placebo across 52 weeks, with the primary endpoint being the proportion of patients achieving transfusion-free status from Week 4 through Week 52. That endpoint is harder and more clinically legible than the hemoglobin-response measure used in RISE UP, which enrolled 207 participants and demonstrated its primary endpoints in the double-blind period. The pivot to transfusion-free status as the confirmatory bar reflects exactly the kind of outcome the FDA wants before converting an accelerated approval to traditional status. Historically, roughly half of accelerated approvals have converted to traditional approval, with a median conversion time of about 3.2 years, so Agios is working against a well-understood but unforgiving clock.
The commercial logic is also compounding. Mitapivat posted $20.7 million in worldwide net revenue in Q1 2026, a 138% increase year-over-year, driven by its existing PK deficiency and thalassemia approvals. Sickle cell disease carries a patient population several times larger than either of those indications, and a successful November approval would give Agios a commercial launch window before the REIGNITE readout is required. The drug’s mechanism, lowering 2,3-DPG to reduce sickling and raising ATP to support red blood cell energy demands, is pharmacologically upstream of several existing therapeutic targets, which matters for combination potential and for payer arguments about differentiation.
The single number to track between now and November 1 is the hemoglobin response rate from the RISE UP Phase 3 double-blind period: the FDA’s willingness to grant accelerated approval rests on whether that surrogate endpoint is deemed reasonably likely to predict clinical benefit, and any signal in the advisory or review process that the agency wants to revisit that reasoning would alter the entire timeline for both approval and REIGNITE’s design adequacy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
